Filing Details

Accession Number:
0001739614-23-000016
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-02 16:17:17
Reporting Period:
2023-03-01
Accepted Time:
2023-03-02 16:17:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1739614 Inhibrx Inc. INBX Biological Products, (No Disgnostic Substances) (2836) 824257312
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1766433 P. Brendan Eckelman C/O Inhibrx, Inc.
11025 North Torrey Pines Road, Suite 200
La Jolla CA 92037
Chief Scientific Officer No Yes No No
1821294 Eckelman Living Trust Dated February 5, 2014 C/O Inhibrx, Inc.
11025 North Torrey Pines Road, Suite 200
La Jolla CA 92037
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-03-01 39,600 $24.20 2,035,953 No 4 S Indirect By the Eckelman Living Trust dated February 5, 2014
Common Stock Disposition 2023-03-01 400 $24.71 2,035,553 No 4 S Indirect By the Eckelman Living Trust dated February 5, 2014
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By the Eckelman Living Trust dated February 5, 2014
No 4 S Indirect By the Eckelman Living Trust dated February 5, 2014
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 160,000 Indirect By trust
Common Stock 160,000 Indirect By trust
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Eckelman Living Trust dated February 5, 2014.
  2. The shares were sold in multiple transactions at prices ranging from $23.70 to $24.67, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  3. These securities are directly owned by the Eckelman Living Trust dated February 5, 2014. Brendan P. Eckelman is the trustee of the Eckelman Living Trust dated February 5, 2014 and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Eckelman Living Trust dated February 5, 2014.
  4. The shares were sold in multiple transactions at prices ranging from $24.70 to $24.73, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
  5. These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor son. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.
  6. These securities are directly owned by a trust, for the benefit of Brendan P. Eckelman's minor daughter. Brendan P. Eckelman is the trustee of the trust, and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the trust.